A new testing platform using fingerstick blood for quantitative antibody response evaluation after SARS-CoV-2 vaccination

References

• WHO Coronavirus (COVID-19) Dashboard. WHO Coronavirus (COVID-19) Dashboard 2021 https://covid19.who.int.
   Google Scholar
• Robbiani DF, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020;584:437–442. doi:10.1038/s41586-020-2456-9.
   PubMed Web of Science ®Google Scholar
• Wang C, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020;11:2251. doi:10.1038/s41467-020-16256-y.
   PubMed Web of Science ®Google Scholar
• Zost SJ, et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020;584:443–449.
   PubMed Web of Science ®Google Scholar
• Liu L, et al. Potent neutralizing antibodies against multiple epitopes on SARSCoV-2 spike. Nature. 2020;584:450–456.
   PubMed Web of Science ®Google Scholar
• Rogers TF, et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020;369:956–963. doi:10.1126/science.abc7520.
   PubMed Web of Science ®Google Scholar
• Anderson EJ, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020;383:2427–2438. doi:10.1056/NEJMoa2028436.
   PubMed Web of Science ®Google Scholar
• Krammer F, et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med. 2021;384:1372–1374. doi:10.1056/NEJMc2101667.
   PubMed Web of Science ®Google Scholar
• Folegatti PM, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet. 2020;396:467–478. doi:10.1016/S0140-6736(20)31604-4.
   PubMed Web of Science ®Google Scholar
• Ramasamy MN, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults(COV002): a single-blind, randomised, controlled, phase 2/3 tria. Lancet. 2020;396:1979–1993.
   PubMed Web of Science ®Google Scholar
• Richmond P, et al. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397:682–694. doi:10.1016/S0140-6736(21)00241-5.
   PubMed Web of Science ®Google Scholar
• Huang Q, et al. A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2. Nature Commun. 2021;12:776. doi:10.1038/s41467-021-21037-2.
   PubMed Web of Science ®Google Scholar
• Iyer AS, et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol. 2020;5:eabe0367. doi:10.1126/sciimmunol.abe.0367.
   PubMed Web of Science ®Google Scholar
• Thompson MG, et al. Interim estimates of vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021. MMWR. 2021;70:495–500.
   PubMed Web of Science ®Google Scholar
• Hall VJ, et al. Effectiveness of BNT162b2 mRNA vaccine against infection and covid-19 vaccine coverage in healthcare workers in england, multicenter prospective cohort study (the SIREN study). Lancet. 2021;397:1725–1735.
   PubMed Web of Science ®Google Scholar
• Karp DG, et al. A serological assay to detect SARS-CoV-2 antibodies in at-home collected finger-prick dried blood spots. Sci Rep. 2020;10:20188. doi:10.1038/s41598-020-76913-6.
   PubMed Web of Science ®Google Scholar
• Du J, et al. A high-throughput anti-SARS-CoV-2 IgG testing platform for COVID-19. J Virol Methods. 2021. doi:10.1016/j.jviromet.2020.114009.
   Web of Science ®Google Scholar
• Corbett KS, et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N Engl J Med. 2020;383:1544–1555.
   PubMed Web of Science ®Google Scholar
• Jackson LA, et al. An mRNA vaccine against SARS-CoV-2 – preliminary report. N Engl J Med. 2020;383:1920–1931.
   PubMed Web of Science ®Google Scholar
• Wang Z, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021;592:616.
   PubMed Web of Science ®Google Scholar
• Sahin U, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586:594–599.
   PubMed Web of Science ®Google Scholar
• Ebinger J, et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med. 2021. doi:10.1038/s41591-021-01325-6.
   PubMed Web of Science ®Google Scholar
• Saadat S, et al. Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2. JAMA. 2021. doi:10.1001/jama.2021.3341.
   PubMed Web of Science ®Google Scholar
• Marot S, et al. Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. Nat Commun. 2021;12:844. doi:10.1038/s41467-021-21111-9.
   PubMed Web of Science ®Google Scholar
• Steensels D, et al. Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273. JAMA. 2021. doi:10.1001/jama.2021.15125.
   PubMed Web of Science ®Google Scholar
• Dogan M, et al. SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus. Commun Biol. 2021;4:129. doi:10.1038/s42003-021-01649-6.
   PubMed Web of Science ®Google Scholar
• Khoury D, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021. doi:10.1038/s41591-021-01377-8.
   PubMed Web of Science ®Google Scholar